Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.
We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted.
Schmidinger
M
M
Department of Internal Medicine I, Division of Clinical Oncology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Wenzel
C
C
Locker
G J
GJ
Muehlbacher
F
F
Steininger
R
R
Gnant
M
M
Crevenna
R
R
Budinsky
A C
AC
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004337:Drug Carriers; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015993:Life Tables; D008081:Liposomes; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010166:Palliative Care; D010865:Pilot Projects; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin